Compare Alcon AG (ALC) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Omnicom Group Inc. — how do they compare? Alcon AG trades at $66.86 (market cap $32.69B), while Omnicom Group Inc. trades at $78.81 (market cap $23.04B). The key difference: Alcon AG is the larger of the two by market cap, and Omnicom Group Inc. pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| ALC | OMC | |
|---|---|---|
Market Cap | $32.69B | $23.04B |
Sector | Health | Media |
52-Week High | $92.22 | $85.80 |
52-Week Low | $62.02 | $67.27 |
Enterprise Value | $36.28B | $30.27B |
Dividend Yield | 0.54% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
OMC trades at $80.84, up 2.82% today, with a bullish technical outlook supported by moving averages and a consensus price target of $105.75. Recent Q1 2026 earnings beat expectations with EPS of $1.90 versus $1.82 expected, while revenue grew to $17.27B in 2025. The company announced new partnerships with IBM and Netflix, enhancing its media agency footprint, and declared a $0.80 dividend payable in July 2026.
The stock presents value with a low P/E of 12.16 and P/S of 0.93, but net income turned negative in 2025, posing a risk. Analyst sentiment is mixed with 32% buy ratings, reflecting optimism about growth initiatives against profitability concerns. Investors should weigh the attractive valuation and strong cash flow against execution risks in a competitive advertising market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
